IGEM:IMPERIAL/2008/Projects/B. subtilis Chassis

From OpenWetWare

Jump to: navigation, search

Contents

B.Subtilis related databases


Chassis

To B.subtilis or not to B.subtilis, that is THE question

The publishing of the B.subtilis genome[1] may allow simple ways to obtain sequence for potentially useful promoters for the B.subtilis chassis

Vector

E.coli plasmids cannot replicate in B.subtilis and so regular biobricks are not usable in such a chassis.

In labs, constructs called shuttle primers capable of replicating in both species are used and often created by merging together an E.coli vector and a B.subtilis vector. One such B.subtilis vector is pC194[2].

pC194 requires a DNA sequence approxiamtely 1300bp[3] in length that could be potentially cloned into the regular biobrick vector

Given the activity of B.subtilis degrading E.coli derived plasmids however. It may be possible to utilise PCR for plasmid production and selection of transformants in B.subtilis to by-pass this issue, or to produce the plasmid in B.subtilis which would be more difficult.

Thonly other option would be to use the Cambridge 2007 approach and attempt to produce a modified shuttle vector to BioBrick standard

Promoters

Constitutive promoters

Assay and characterisation of a strong promoter element from B. subtilis [4]. Despite the pigdin English this paper describes the identification of a strong promoter element from B. subtilis - the authors already put it into an expression vector. It is stronger than the P43 promoter and is perhaps one we could make use of for constitutive expression?

A derepression system based on the Bacillus subtilis sporulation pathway is described [5] - an example of an engineering approach to a derepression-based control of gene expression in B. subtilis and an example of a heterologous secreted protein being expressed into the medium and subsequent assaying for that secreted protein.

Use of basal transcription promoters, potentially the promoter for one or various rRNAs, P3 promoter[6], RNAP subunit gene promoters and metablic gene promoters.

Annotated B.subtilis genome

Metabolic Pathways of B.subtilis

Probably ideal to pick a few (say 5) and characterise in order to find relative levels for use

1 rRNA promoter
1+ Metabolic related promoter (potential inducibility)
1 RNAP subunit promoter
P3 promoter
Another basaly transcribe sequence

All non-constiutive promoters should remain functional in B.subtilis though leaky (basal) transcription rate will however be different, the key promoter is the one at the start of the chain...

RBS

On a preliminary basis, there appears to be some issues realted to the B.subtilis RBS, particularly the sequence and also codon usage with the normal AUG start becoming UUG in at least some B.subtilis vectors[7]

The codon usage in B.subtilis indicates that UUG encodes leucine not methionine and as such the UUG methionine found on the B.subtilis vector[8], indicating the issue may be confined to just the start codon

This will need looking into if B.subtilis is to be used

Reference

  1. Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessières P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Cordani JJ, Connerton IF, Cummings NJ, Daniel RA, Denziot F, Devine KM, Düsterhöft A, Ehrlich SD, Emmerson PT, Entian KD, Errington J, Fabret C, Ferrari E, Foulger D, Fritz C, Fujita M, Fujita Y, Fuma S, Galizzi A, Galleron N, Ghim SY, Glaser P, Goffeau A, Golightly EJ, Grandi G, Guiseppi G, Guy BJ, Haga K, Haiech J, Harwood CR, Hènaut A, Hilbert H, Holsappel S, Hosono S, Hullo MF, Itaya M, Jones L, Joris B, Karamata D, Kasahara Y, Klaerr-Blanchard M, Klein C, Kobayashi Y, Koetter P, Koningstein G, Krogh S, Kumano M, Kurita K, Lapidus A, Lardinois S, Lauber J, Lazarevic V, Lee SM, Levine A, Liu H, Masuda S, Mauël C, Médigue C, Medina N, Mellado RP, Mizuno M, Moestl D, Nakai S, Noback M, Noone D, O'Reilly M, Ogawa K, Ogiwara A, Oudega B, Park SH, Parro V, Pohl TM, Portelle D, Porwollik S, Prescott AM, Presecan E, Pujic P, Purnelle B, Rapoport G, Rey M, Reynolds S, Rieger M, Rivolta C, Rocha E, Roche B, Rose M, Sadaie Y, Sato T, Scanlan E, Schleich S, Schroeter R, Scoffone F, Sekiguchi J, Sekowska A, Seror SJ, Serror P, Shin BS, Soldo B, Sorokin A, Tacconi E, Takagi T, Takahashi H, Takemaru K, Takeuchi M, Tamakoshi A, Tanaka T, Terpstra P, Togoni A, Tosato V, Uchiyama S, Vandebol M, Vannier F, Vassarotti A, Viari A, Wambutt R, Wedler H, Weitzenegger T, Winters P, Wipat A, Yamamoto H, Yamane K, Yasumoto K, Yata K, Yoshida K, Yoshikawa HF, Zumstein E, Yoshikawa H, and Danchin A. . pmid:9384377. PubMed HubMed [1]
  2. Horinouchi S and Weisblum B. . pmid:6950931. PubMed HubMed [2]
  3. Dagert M, Jones I, Goze A, Romac S, Niaudet B, and Ehrlich SD. . pmid:6323171. PubMed HubMed [3]
  4. Zhang AL, Liu H, Yang MM, Gong YS, and Chen H. . pmid:17210127. PubMed HubMed [7]
  5. Nijland R, Veening JW, and Kuipers OP. . pmid:17293533. PubMed HubMed [8]
  6. Leelakriangsak M and Zuber P. . pmid:17158663. PubMed HubMed [4]
  7. McLaughlin JR, Murray CL, and Rabinowitz JC. . pmid:6793593. PubMed HubMed [5]
  8. Shields DC and Sharp PM. . pmid:3118331. PubMed HubMed [6]
All Medline abstracts: PubMed HubMed
Personal tools